MA41337A - Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 - Google Patents

Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3

Info

Publication number
MA41337A
MA41337A MA041337A MA41337A MA41337A MA 41337 A MA41337 A MA 41337A MA 041337 A MA041337 A MA 041337A MA 41337 A MA41337 A MA 41337A MA 41337 A MA41337 A MA 41337A
Authority
MA
Morocco
Prior art keywords
receptor modulators
derivatives used
piperazine derivatives
cxcr3 receptor
hydroxyalkyl piperazine
Prior art date
Application number
MA041337A
Other languages
English (en)
Inventor
Eva Caroff
Emmanuel Meyer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA41337A publication Critical patent/MA41337A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (i) dans laquelle n, x, r<sup>1</sup> et r<sup>2</sup> sont tels que définis dans la description; des sels pharmaceutiquement acceptables de ceux-ci, et l'utilisation de tels composés en tant que médicaments, en particulier en tant que modulateurs du récepteur cxcr3
MA041337A 2015-01-15 2016-01-14 Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 MA41337A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2015050696 2015-01-15

Publications (1)

Publication Number Publication Date
MA41337A true MA41337A (fr) 2017-11-22

Family

ID=55129886

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041337A MA41337A (fr) 2015-01-15 2016-01-14 Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3

Country Status (38)

Country Link
US (1) US10053457B2 (fr)
EP (1) EP3245203B1 (fr)
JP (1) JP6337218B2 (fr)
KR (1) KR101967083B1 (fr)
CN (1) CN107250133B (fr)
AR (1) AR103414A1 (fr)
AU (1) AU2016207988B2 (fr)
BR (1) BR112017015093A2 (fr)
CA (1) CA2972952C (fr)
CL (1) CL2017001831A1 (fr)
CO (1) CO2017008156A2 (fr)
CY (1) CY1121361T1 (fr)
DK (1) DK3245203T3 (fr)
EA (1) EA032927B1 (fr)
ES (1) ES2709985T3 (fr)
HK (1) HK1246789B (fr)
HR (1) HRP20190024T1 (fr)
HU (1) HUE042559T2 (fr)
IL (1) IL253411B (fr)
LT (1) LT3245203T (fr)
MA (1) MA41337A (fr)
MX (1) MX2017009288A (fr)
MY (1) MY187614A (fr)
NZ (1) NZ734542A (fr)
PE (1) PE20171100A1 (fr)
PH (1) PH12017501280B1 (fr)
PL (1) PL3245203T3 (fr)
PT (1) PT3245203T (fr)
RS (1) RS58349B1 (fr)
SA (1) SA517381905B1 (fr)
SG (1) SG11201705617XA (fr)
SI (1) SI3245203T1 (fr)
TN (1) TN2017000278A1 (fr)
TR (1) TR201900680T4 (fr)
TW (1) TWI693221B (fr)
UA (1) UA119805C2 (fr)
WO (1) WO2016113344A1 (fr)
ZA (1) ZA201705486B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR103399A1 (es) * 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
TWI693221B (zh) * 2015-01-15 2020-05-11 瑞士商愛杜西亞製藥有限公司 作為ｃｘｃｒ３受體調節劑之羥烷基六氫吡衍生物
WO2018011265A1 (fr) * 2016-07-13 2018-01-18 Idorsia Pharmaceuticals Ltd Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
WO2020060964A1 (fr) * 2018-09-18 2020-03-26 Alxerion Biotech Corp. Dérivés de 1, 2, 4-oxadiazole et leurs utilisations
JP2024504785A (ja) * 2021-01-28 2024-02-01 イドーシア ファーマシューティカルズ リミテッド ピペラジニル－チアゾール誘導体の結晶形
US20250381184A1 (en) 2022-09-09 2025-12-18 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370558B1 (fr) 2001-01-23 2005-08-24 Eli Lilly And Company Derives de piperazine et de piperidine en tant qu'agonistes du recepteur de la melanocortine
WO2002059107A1 (fr) 2001-01-23 2002-08-01 Eli Lilly And Company Piperidines/piperazines substituees utilisees comme agonistes du recepteur de melanocortine
WO2002079146A2 (fr) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Composes utiles comme modulateurs des recepteurs de la melanocortine et compositions pharmaceutiques renfermant ceux-ci
MXPA04012393A (es) 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
WO2005035534A1 (fr) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Composes a anneau bicyclique heterocyclique et a anneau tricyclique heterocyclique et medicaments les contenant
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20050130954A1 (en) 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US20060276465A1 (en) 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
ES2611604T3 (es) 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
CN101146793A (zh) 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
US7879838B2 (en) 2005-02-16 2011-02-01 Schering Corporation Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
MX2007010068A (es) 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
CA2598460C (fr) 2005-02-16 2013-05-07 Schering Corporation Pyridyle a liaison amine et piperazine-piperidines substituees a activite agoniste cxcr3
MX2007009946A (es) 2005-02-16 2007-09-26 Schering Corp Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3.
EP1856098B1 (fr) 2005-02-16 2012-08-01 Schering Corporation Piperazine-piperidines pyrazinyl substituees a activite antagoniste des cxcr3
ZA200800309B (en) 2005-06-22 2009-10-28 Chemocentryx Inc Azaindazole compounds and methods of use
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20080312215A1 (en) 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
US7781437B2 (en) 2005-10-11 2010-08-24 Schering Corporation Substituted heterocyclic compounds with CXCR3 antagonist activity
EP1951234A2 (fr) 2005-10-18 2008-08-06 Janssen Pharmaceutica N.V. Methode d'inhibition de la kinase flt3
US20090143413A1 (en) 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
US20070126158A1 (en) 2005-12-01 2007-06-07 3M Innovative Properties Company Method of cleaning polymeric mold
US20100286191A1 (en) 2005-12-12 2010-11-11 Samuel Rachel G 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators
WO2007076318A2 (fr) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Antagonistes de cxcr3 dérivés du camphre
US20090030012A1 (en) 2006-02-23 2009-01-29 Adams Alan D Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators
AU2007227425A1 (en) 2006-03-21 2007-09-27 Pharmacopeia, Inc. Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity
EP2397138B1 (fr) 2006-04-20 2013-12-11 Janssen Pharmaceutica NV Dérivés d'amides aromatiques comme inhibiteurs de la kinase C-KIT
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
US7902199B2 (en) 2006-07-14 2011-03-08 Schering Corporation Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity
WO2008013622A2 (fr) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Amides azocycliques fongicides
MX2009006871A (es) 2006-12-22 2009-07-07 Schering Corp Compuestos heterociclicos con actividad antagonista de cxcr3.
WO2008091594A2 (fr) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Mélanges fongicides
BRPI0806214A2 (pt) 2007-01-25 2011-08-30 Du Pont composto, método para o controla das doenças vegetais causadas por patogenos vegetais fúngicos oomycete e composições fungicidas
MX2010001400A (es) 2007-08-03 2010-04-22 Schering Corp Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas.
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
WO2009079490A1 (fr) 2007-12-18 2009-06-25 Schering Corporation Procédé et intermédiaires pour la synthèse de pipérazines substituées hétérocycliques avec une activité antagoniste du cxcr3
JP5529044B2 (ja) 2008-01-25 2014-06-25 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性複素環化合物
WO2009094407A2 (fr) 2008-01-25 2009-07-30 E. I. Du Pont De Nemours And Company Amides fongicides
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
PT2280965E (pt) 2008-04-30 2012-11-13 Bayer Cropscience Ag Ésteres e tioésteres de ácido tiazol-4-carboxílico como agentes para a protecção de plantas
KR20110067052A (ko) 2008-10-01 2011-06-20 바이엘 크롭사이언스 아게 식물 보호제로서의 헤테로사이클릴 치환된 티아졸
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
PL2358709T3 (pl) 2008-12-02 2014-06-30 Du Pont Grzybobójcze związki heterocykliczne
CN102292334A (zh) 2008-12-11 2011-12-21 拜尔农作物科学股份公司 噻唑基肟醚和腙植物保护剂
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
EP2272846A1 (fr) 2009-06-23 2011-01-12 Bayer CropScience AG Dérivés de thiazolylpipéridine en tant que fongicide
GEP20146079B (en) 2009-08-12 2014-04-25 Syngenta Participations Ag Microbiocidal heterocycles
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
WO2011051243A1 (fr) 2009-10-29 2011-05-05 Bayer Cropscience Ag Combinaisons de composé actif
WO2011051244A1 (fr) 2009-10-30 2011-05-05 Bayer Cropscience Ag Dérivés d'hétéroarylpipéridine et d'hétéroarylpipérazine
KR101808074B1 (ko) 2009-12-21 2017-12-12 바이엘 크롭사이언스 악티엔게젤샤프트 살진균제로 사용되는 비스(디플루오로메틸)피라졸
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
MX2012012460A (es) 2010-04-28 2012-11-21 Bayer Cropscience Ag Derivados de cetoheteroarilpiperidina y de cetoheteroarilpiperazin a como fungicidas.
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
EP2571866A1 (fr) 2010-05-20 2013-03-27 E.I. Du Pont De Nemours And Company Oximes et hydrazones fongicides
BR112012030184A2 (pt) 2010-05-27 2015-12-29 Bayer Cropscience Ag derivados de ácido piridinilcarboxílico como fungicidas
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
UA112534C2 (uk) 2010-10-27 2016-09-26 Байєр Інтеллектуал Проперті Гмбх Похідні гетероарилпіперидину, проміжні сполуки, композиція для боротьби із шкідливими фітопатогенними грибами та спосіб її виготовлення
CN103228645A (zh) 2010-11-25 2013-07-31 先正达参股股份有限公司 杀微生物杂环
MX2013006936A (es) 2010-12-17 2013-07-22 Du Pont Ambas azociclicas fungicidas.
KR101848116B1 (ko) 2011-02-01 2018-04-11 바이엘 인텔렉쳐 프로퍼티 게엠베하 살진균제로서의 헤테로아릴 피페리딘 및 헤테로아릴 피페라진 유도체
WO2012107475A1 (fr) 2011-02-10 2012-08-16 Syngenta Participations Ag Dérivés de pyrazole microbiocides
CN103347879A (zh) 2011-02-10 2013-10-09 先正达参股股份有限公司 杀微生物的吡唑衍生物
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
JP5959646B2 (ja) 2011-09-15 2016-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺菌剤としてのピペリジンピラゾール類
US20140243371A1 (en) 2011-10-18 2014-08-28 Syngenta Participations Ag Microbiocidal pyrazole derivatives
US20140228372A1 (en) 2011-10-18 2014-08-14 Syngenta Participations Ag Microbiocidal pyrazole derivatives
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
US20150011565A1 (en) 2012-01-25 2015-01-08 Spinifex Pharmaceuticals Pty Ltd Heterocyclic Compounds and Methods For Their Use
EP2809668B1 (fr) * 2012-02-02 2017-04-12 Actelion Pharmaceuticals Ltd. Composés de 4-(benzoimidazol-2-yle)-thiazole et dérivés aza associés
US20160007606A1 (en) 2012-03-02 2016-01-14 Syngenta Participations Ag Microbiocidal pyrazole derivatives
IN2012DE00621A (fr) 2012-03-02 2015-07-17 Syngenta Participations Ag
TWI570120B (zh) * 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
WO2014062938A1 (fr) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Modulateurs du récepteur gamma orphelin associé aux rétinoïdes (rory)
WO2014075873A1 (fr) 2012-11-13 2014-05-22 Syngenta Participations Ag Dérivés microbicides de pyrazole
WO2014075874A1 (fr) 2012-11-13 2014-05-22 Syngenta Participations Ag Dérivés microbicides de pyrazole
WO2014092100A1 (fr) 2012-12-11 2014-06-19 武田薬品工業株式会社 Composé hétérocyclique
JP6430494B2 (ja) 2013-06-24 2018-11-28 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺真菌剤としてのピペリジンカルボン酸誘導体
SG11201600504TA (en) * 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
US9718818B2 (en) 2013-08-22 2017-08-01 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR102256A1 (es) * 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
TWI693221B (zh) * 2015-01-15 2020-05-11 瑞士商愛杜西亞製藥有限公司 作為ｃｘｃｒ３受體調節劑之羥烷基六氫吡衍生物

Also Published As

Publication number Publication date
KR20170102010A (ko) 2017-09-06
TW201632519A (zh) 2016-09-16
MX2017009288A (es) 2017-10-11
JP6337218B2 (ja) 2018-06-06
ZA201705486B (en) 2019-06-26
PT3245203T (pt) 2019-02-08
IL253411A0 (en) 2017-09-28
PH12017501280A1 (en) 2018-01-15
SA517381905B1 (ar) 2021-04-01
EP3245203B1 (fr) 2018-11-14
EA032927B1 (ru) 2019-08-30
US20180009799A1 (en) 2018-01-11
CA2972952C (fr) 2021-01-05
AR103414A1 (es) 2017-05-10
PH12017501280B1 (en) 2020-10-23
PL3245203T3 (pl) 2019-05-31
TWI693221B (zh) 2020-05-11
IL253411B (en) 2020-08-31
BR112017015093A2 (pt) 2018-04-17
SG11201705617XA (en) 2017-08-30
CA2972952A1 (fr) 2016-07-21
LT3245203T (lt) 2019-02-11
US10053457B2 (en) 2018-08-21
JP2018502161A (ja) 2018-01-25
PE20171100A1 (es) 2017-08-07
TN2017000278A1 (en) 2019-01-16
UA119805C2 (uk) 2019-08-12
KR101967083B1 (ko) 2019-04-08
AU2016207988A1 (en) 2017-08-31
CN107250133B (zh) 2020-09-15
HRP20190024T1 (hr) 2019-02-22
HUE042559T2 (hu) 2019-07-29
CN107250133A (zh) 2017-10-13
RS58349B1 (sr) 2019-03-29
DK3245203T3 (en) 2019-02-18
CO2017008156A2 (es) 2017-11-30
WO2016113344A1 (fr) 2016-07-21
CL2017001831A1 (es) 2018-05-11
EP3245203A1 (fr) 2017-11-22
EA201791600A1 (ru) 2018-03-30
NZ734542A (en) 2023-02-24
ES2709985T3 (es) 2019-04-22
TR201900680T4 (tr) 2019-02-21
SI3245203T1 (sl) 2019-03-29
CY1121361T1 (el) 2020-05-29
MY187614A (en) 2021-10-04
AU2016207988B2 (en) 2019-08-15
HK1246789B (en) 2019-11-22

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu&#39;inhibiteurs de kinase
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
MA39317A1 (fr) Dérivés de nucléosides à substitution 4&#39;-difluorométhyle utilisés en tant qu&#39;inhibiteurs de la réplication de l&#39;arn du virus de la grippe
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
PH12016501440A1 (en) Novel heterocyclic compounds
CU20170105A7 (es) Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu&#39; agents de blocage des canaux calciques de type t
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
MA37142A2 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
ECSP17069696A (es) Compuestos novedosos
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d&#39;orexine
MX394108B (es) Derivados de indol n-sustituidos.
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MA38854A1 (fr) Dérivés amides utilisés en tant qu&#39;antagonistes des récepteurs de l&#39;acide lysophosphatidique